RLS started in 2000 has several departments focusing on all areas of biotechnology.Some of the areas which RLS focused where:
- Plant biotechnology
- Plant Tissue culture
- Industrial Biotechnology
- Alternate Energy- Biodiesel, Solar etc
- Clinical trials
- Clinical diagnostics
- Stem cells
- Plasma fractionation
- Chemicals API
Except Plasma fractionation and Biopharmaceuticals all other departments are closed.
What is the strategy behind this?
After a decade of trial why RLS moved from Diversification to Concentration.
One of the key reasons might be to focus on Large scale Manufacturing rather than services.
If you carefully analyse, all the service sectors related projects are closed completely. Projects related to manufacturing are focused.
Is it right move or not , time should answer.
OK what Senior Management feels about RLS. See there interview below.
Former Employee of RLS who initiated and developed all Biosimilar MAb projects.